Alzamend Neuro ALZN
NASDAQ ALZN
$1.25 -0.05 (-3.85%)
At close: Oct 21, 2026 · 4:00 PM EDT

Alzamend Neuro (ALZN) Total Non-Current Liabilities (2024)

Updated

Alzamend Neuro (ALZN) recorded Total Non-Current Liabilities of $4.3 million in fiscal Q3 2024 (quarter ended Jan 31, 2024).

Analysis

Alzamend Neuro (ALZN) Total Non-Current Liabilities (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 60.66 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 105.50 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 106.45 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 80.25 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 48.34 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 33.91 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 78.66 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 35.10 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 97.04 Bn
10 Alzamend Neuro 5.73 Mn -9.73 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jan 31, 2024 4.30 Mn
API Access

Alzamend Neuro Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=ALZN&period=max&api_key=YOUR_API_KEY